

Ken-ichi Ogawara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7806934/publications.pdf>

Version: 2024-02-01

7
papers

489
citations

1478505

6
h-index

1872680

6
g-index

7
all docs

7
docs citations

7
times ranked

815
citing authors

#	ARTICLE	IF	CITATIONS
1	PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. International Journal of Pharmaceutics, 2011, 412, 132-141.	5.2	121
2	Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. International Journal of Pharmaceutics, 2008, 359, 272-279.	5.2	112
3	In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. Journal of Controlled Release, 2009, 133, 4-10.	9.9	91
4	Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. International Journal of Pharmaceutics, 2008, 359, 234-240.	5.2	78
5	Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. International Journal of Pharmaceutics, 2008, 353, 28-34.	5.2	72
6	A novel approach to overcome multidrug resistance: Utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors. European Journal of Pharmaceutical Sciences, 2014, 62, 274-280.	4.0	15
7	Toward the schematization of the factors which affect the enhanced permeability and retention effect. Drug Delivery System, 2018, 33, 105-114.	0.0	0